Revised. Amendments from Version 1
==================================

We have added written protocols for conditioned pain modulation and undertaking skin biopsy samples as supplementary information. We have also provided clarification in some of the terminology used (for instance more precision in the term environment) and the rationale for: performing EEG, threshold tracking studies and including a list of body sites to map pain location. We have clarified the exclusion criteria in the longitudinal cohorts, and we have added further explanations on our data management procedures.

Introduction
============

Neuropathic pain affects 7--10% of the general population ^[@ref-1]^ and has a major impact on physical health, psychological health and quality of life ^[@ref-2]^. The response to analgesic treatment is often inadequate with only 40--60% of patients achieving partial relief, often at the cost of adverse effects ^[@ref-3]^. The prevalence of neuropathic pain will increase due to the increasing prevalence of predisposing conditions, such as diabetes mellitus, and ageing, which is associated with neuropathic pain ^[@ref-1]^. There is an urgent clinical need to translate an increased preclinical level of understanding of neuropathic into clinical practice. In particular we need to understand the pathophysiology of neuropathic pain in clinical cohorts.

Neuropathic pain arises as a consequence of a disease or lesion in the somatosensory nervous system ^[@ref-4]^. However, not all patients with such a lesion develop neuropathic pain. We do not understand why only a sub-group of patients with the same disease or neurological lesion develop neuropathic pain. The severity and impact of neuropathic pain vary between individuals with similar conditions ^[@ref-5]^ and are unpredictable. A plausible explanation for the variation in neuropathic pain prevalence and severity is a complex interaction between genetic, psychosocial, and clinical risk factors in a vulnerable individual ^[@ref-6]--\ [@ref-8]^.

A recent and significant advance in neuropathic pain research has been the development of clinical tools, such as standardised questionnaires and quantitative sensory testing for sensory phenotyping, that differentiate and stratify neuropathic pain ^[@ref-9]--\ [@ref-13]^. We have entered an era whereby patients can be phenotyped in unprecedented detail in terms of sensory profile, psychological factors and physiological measures such as nerve excitability testing. We have the opportunity to combine major advances in phenotyping with genomics to improve our understanding of neuropathic pain.

Aims and objectives
===================

DOLORisk is a multi-centre observational study that aims to understand the risk factors and determinants for neuropathic pain.

Primary objectives
------------------

The primary objectives of DOLORisk are (1) to identify the influence of demographic, psychological and clinical factors on the risk of developing and maintenance of neuropathic pain, and (2) to study the association of genetic factors with the risk of developing and maintaining neuropathic pain.

Secondary objectives
--------------------

DOLORisk also aims to determine if patient stratification using physiological and psychological factors can predict neuropathic pain risk and progression. Based on the analysis of these risk factors, the study will lead to the development of a risk model for neuropathic pain, combining measurable genetic and environmental factors.

Methods
=======

Study design
------------

The first step was to develop a protocol that would be used by all participating centres to identify and characterise people with neuropathic pain. The instruments chosen to phenotype DOLORisk participants were the object of a consensus meeting between the recruitment centres in October 2015. This was based on a recent international consensus on phenotyping neuropathic pain (NeuroPPIC), led by the Special Interest Group on Neuropathic Pain (NeuPSIG), of the International Association for the Study of Pain ^[@ref-14]^. The respective merits and reported accuracy of available scales, questionnaires and self-reported measures were discussed and the following were included in the final DOLORisk protocol ( [Table 1](#T1){ref-type="table"}). The DOLORisk protocol has been aligned across all recruitment centres to make data integration possible. The "core" protocol consists of questionnaires only. All participants recruited complete the core protocol and are classified according to the presence and extent of any neuropathic pain. This information will be used to look for genetic and basic clinical risk factors using the methods outlined below. The "extended" protocol consists of more detailed phenotyping and uses multiple tools. The tools used for any subject depend on the recruitment centre to which he or she is recruited ( [Table 2](#T2){ref-type="table"}). A sub-group of participants will be recruited through the extended protocol.

###### Questionnaires of the DOLORisk protocol.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Category                                 Questionnaire                       Core   Extended                           Reference
  ---------------------------------------- ----------------------------------- ------ ---------------------------------- ---------------------------------
  **Demographics**                         Age, gender, years in education,\   X      X                                  
                                           working status, weight, height                                                

  **Characterisation of**\                 Presence and duration of pain       X      X                                  
  **pain**                                                                                                               

  **Family history**                       Family history of chronic pain             X                                  

  **Pain medication**                      Currently taking pain medication    X      X                                  

  Brief Pain Inventory -- Usefulness of\                                       X      Cleeland and Ryan ^[@ref-15]^      
  medication                                                                                                             

  Adherence to medication                                                      X                                         

  **Pain severity**                        Chronic Pain Grade                  X      X                                  Von Korff, *et al*. ^[@ref-16]^

  Brief Pain Inventory -- Pain Severity                                        X      Cleeland and Ryan ^[@ref-15]^      

  **Pain quality**                         DN4 Questionnaire                   X      X                                  Bouhassira, *et al*. ^[@ref-9]^

  DN4 Examination                                                              X                                         

  Neuropathic Pain Symptom Inventory                                           X      Bouhassira, *et al*. ^[@ref-17]^   

  PainDETECT                                                                   X      Freynhagen, *et al*. ^[@ref-10]^   

  **Pain location**                        List of locations                   X      X                                  

  Body map                                                                     X                                         

  **Pain interference**                    PROMIS Pain Interference                   X                                  Cella, *et al*. ^[@ref-19]^

  **Pain catastrophizing**                 Pain Catastrophizing Scale          X      X                                  Sullivan, *et al*. ^[@ref-20]^

  **Health status and**\                   EQ-5D-5L                            X      X                                  Herdman, *et al*. ^[@ref-21]^
  **quality of life**                                                                                                    

  PROMIS Depression                        4a                                  8a     Cella, *et al*. ^[@ref-19]^        

  PROMIS Anxiety                           4a                                  8a                                        

  PROMIS Sleep Disturbance                 4a                                  8a                                        

  PROMIS Fatigue                                                               X                                         

  Trauma                                   X                                   X                                         

  **Disease specific**\                    Michigan Neuropathy Screening\             X                                  Feldman, *et al*. ^[@ref-18]^
  **(diabetic neuropathy)**                Instrument                                                                    

  **Personality**                          Ten Item Personality Inventory      X      X                                  Gosling, *et al*. ^[@ref-22]^

  International Personality Item Pool\                                         X      Goldberg ^[@ref-23]^               
  (Emotional Stability)                                                                                                  

  **Lifestyle**                            Smoking                             X      X                                  Campbell, *et al*. ^[@ref-24]^

  Alcohol                                  X                                   X                                         

  International Physical Activity\                                             X      Craig, *et al*. ^[@ref-25]^        
  Questionnaire                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------

###### Summary of tests performed during the DOLORisk protocol.

  ---------------------------------------------------------------------------------------------------------
  Cohort             Protocol   Neurological\   TCSS   TNSn   Skin\    QST   NCS   EEG   Threshold\   CPM
                                examination                   biopsy                     tracking     
  ------------------ ---------- --------------- ------ ------ -------- ----- ----- ----- ------------ -----
  Population         Core                                                                             

  Diabetes           Extended   X               X             X        X     X     X     X            X

  Traumatic nerve\   Extended   X               X                            X           X            
  injury                                                                                              

  Surgery            Extended   X                                      X                 X            X

  Chemotherapy       Extended   X                      X               X     X           X            

  Extreme\           Extended   X               X                      X     X           X            
  phenotypes                                                                                          
  ---------------------------------------------------------------------------------------------------------

TCSS- Toronto clinical scoring system; TNSn- Total Neuropathy Score -- Nurse; QST- Quantitative sensory testing; EEG - Electroencephalography; CPM- Conditioned pain modulation.

Tools for phenotyping
---------------------

**Questionnaires**

***Demographics***

Demographic information captured includes age, gender, weight, height, years in education, and working status.

***Characterisation of pain***

The presence and duration of pain (and also dysaesthesia) are assessed. Family history of chronic pain is recorded. Pain medication (individual drugs, e.g. paracetamol or gabapentin, and dosage), analgesic relief obtained and adherence to medication are recorded according to the Brief Pain Inventory (BPI) ^[@ref-15]^.

***Pain intensity***

Intensity of the pain is assessed with two questionnaires: the Chronic Pain Grade (CPG) ^[@ref-16]^ over the past three months, and the BPI's subscale for assessment of average pain severity over 24 hours (which uses an 11 point numerical rating scale). One additional item asks about average pain over the past seven days.

***Pain quality***

Neuropathic descriptors of the pain are characterised with three tools: the DN4 ( *Douleur Neuropathique en 4 questions*) ^[@ref-9]^, the Neuropathic Pain Symptom Inventory (NPSI) ^[@ref-17]^, and the painDETECT ^[@ref-10]^. The Michigan Neuropathy Screening Instrument (MNSI) ^[@ref-18]^ is used specifically for diabetic neuropathy.

***Pain location***

The participants are asked to indicate in which body site they feel pain. This is assessed in two ways: a list of body sites and a body map. The participants are asked to identify all the body locations in which they experienced pain over the previous three months, and to mark the pain that bothers them the most. The body sites include: Back pain; Neck or shoulder pain; Facial or dental pain; Headache; Stomach ache or abdominal pain; Pain in the arms; Pain in the hands; Chest pain; Pain in the hips; Pain in the legs or knees; Pain in the feet; Pain throughout the body (widespread pain); Other pain. Using a list of body sites affected by pain provides alignment with pre-existing population cohorts, and is compatible with the recommendations of van Hecke, *et al*. ^[@ref-1]^. This will allow us to test the viability and feasibility of this approach to phenotyping neuropathic pain. Detailed body maps will be available for all participants in the extended protocol, which will provide additional accuracy and also enable direct comparison with the list of body sites.

The core and the extended protocols take a different approach to identify the location in which the participant should be asked to rate pain. The rationale for this is that the recommendation for grading neuropathic pain is based upon pain and clinical signs in a neuroanatomically plausible distribution ^[@ref-26]^. The core protocol is designed for the assessment of neuropathic pain of diverse aetiologies at population level, and there is no prior expectation as to the neuroanatomically plausible distribution. Then, participants are asked to specify body regions in which they experience pain, and choose one body region in which the pain bothers them most. In the core protocol, participants are asked to answer the questions that relates to pain intensity, quality and interference in respect to the body region in which pain bothers them most. The approach in the extended protocol is different because in these cohorts the likely aetiology of neuropathic pain is known and therefore the neuroanatomically plausible distribution is pre-determined. For instance in diabetic neuropathy or chemotherapy induced neuropathy the neuroanatomically plausible distribution is the feet, whereas following post-traumatic nerve injury the neuroanatomically plausible distribution is the innervation territory of the affected nerve. Participants are explicitly asked by the investigator to focus on the neuroanatomically plausible distribution when answering the questions on pain intensity, quality and interference. To capture information on other types of pain we then ask about pain in other body regions.

***Pain interference, quality of life and psychological variables***

The Patient-Reported Outcomes Measurement Information System (PROMIS) ^[@ref-19]^ questionnaires are used to assess various psychological and psychosocial variables. They include depression, anxiety, sleep disturbance, fatigue and pain interference. Two bespoke questions adapted from the existing population data ask about traumatic life experiences. The EQ-5D-5L ^[@ref-21]^ measures quality of life with a visual analogue scale and five items evaluating the impact of pain on the ability of the participant to perform everyday tasks.

Two questionnaires assessing personality and in particular neuroticism are included in the DOLORisk protocol. The Ten-Item Personality Inventory (TIPI) ^[@ref-22]^ evaluates extraversion, agreeableness, conscientiousness, neuroticism, and openness to experience. The 10-item International Personality Item Pool's (IPIP) ^[@ref-23]^ representation of the Goldberg ^[@ref-27]^ markers for Emotional Stability offers a more precise characterisation of neuroticism. Pain catastrophizing behaviours are recorded through the Pain Catastrophizing Scale (PCS) ^[@ref-20]^.

***Lifestyle***

Smoking and alcohol are recorded according to Campbell, *et al.* ^[@ref-24]^ The short form of the International Physical Activity Questionnaire (IPAQ) ^[@ref-25]^ is included in the lifestyle variables to account for physical activity.

Clinical assessment and specialised investigations
--------------------------------------------------

***Neurological examination***

A comprehensive structured upper and lower limb neurological examination is performed to detect clinical signs of a neurological lesion such as a peripheral neuropathy ^[@ref-5],\ [@ref-28]--\ [@ref-30]^. The examination includes assessment of temperature (using Somedic RollTemp, Somedic AB, Sweden), light touch (using 10g monofilament) and pinprick sensation (using 'Neurotip'), joint position sense (proprioception), vibration perception using a 128Hz tuning fork, deep-tendon reflexes (using a Queen square tendon hammer and recorded as present as normal, present with reinforcement, absent or brisk), muscle bulk, and motor power. The clinical findings for a length-dependent neuropathy are quantified with the Toronto Clinical Scoring System (TCSS) ^[@ref-31]^. The Total Neuropathy Score -- Nurse (TNSn) ^[@ref-32]^ is used for chemotherapy-induced neuropathy. For other causes of neuropathic pain the spatial extent of sensory deficits and sensory hypersensitivity is recorded on a body map.

***Nerve conduction studies***

Nerve conduction tests, to confirm the presence of a length dependent neuropathy, are performed in line with those recommended by the American Academy of Neurology and American Association of Electrodiagnostic Medicine ^[@ref-33],\ [@ref-34]^. Sural sensory and peroneal motor nerve conduction studies are performed in one lower extremity. If both studies are normal ^[@ref-33]^ no further tests are performed. If either test is abnormal additional nerve conduction studies are performed that include: ipsilateral tibial motor nerve; contralateral sural sensory nerve, peroneal motor or tibial motor nerves; or ulnar sensory, median sensory, and ulnar motor nerves in one upper extremity. The minimum case definition criterion for electrodiagnostic confirmation of a length dependant neuropathy is an abnormality of any attribute of nerve conduction studies in two separate nerves, one of which is the sural nerve. Variables such as skin temperature, age, height, gender, and weight are measured and accounted for when interpreting nerve conduction tests. Nerve conduction tests are not repeated if study participants have previous results available which were performed within the last 2 years.

***Electroencephalography***

Electroencephalography (EEG) reflects the summated activity of synchronised arrays of brain neurons. Recent studies found correlations between several EEG parameters and pain perception in healthy subjects, suggesting that EEG can identify parameters that relate to the individual\'s way of processing pain. Examining EEG parameters in peripheral neuropathy patients can potentially identify those individual patterns of pain processing which are part of the array of factors that determine the final clinical pain phenotype ^[@ref-35],\ [@ref-36]^. Establishing EEG as an appropriate biomarker for pain perception relies on its accuracy to correctly classify subjects as belonging to the pain or no-pain conditions. In order to achieve this goal we follow the standard statistical steps of multivariate pattern analysis. A range of classifiers that distinguish the painful from the non-painful brain include measures of peak activity within the various EEG frequency bands per electrode, point to point connectivity between each of 64 electrodes, as well as identification of brain networks. This is expected to allow new understanding about the neurophysiological aspects of pain processing in the painful brain. The classification method finally employed will be the one with the highest classification accuracy on a test set after being trained on a separate training set.

***Threshold tracking***

Threshold tracking is an electrophysiological tool that assesses nerve excitability ^[@ref-37]^. Nerve excitability measures are determined by the biophysical properties of myelinated axons and the axon membrane potential. The information obtained about nerve properties is complementary to conventional nerve conduction studies: measurements of action potential amplitude and latency are limited indices of function, providing information only on the number of conducting fibres and the conduction velocity of the fastest, while threshold tracking is sensitive to membrane potential at the site of stimulation ^[@ref-37]^. In DOLORisk several measures of axonal excitability, such as refractoriness, supernormality, strength-duration time constant and threshold electrotonus, are assessed. The excitability measures are recorded from the motor and sensory divisions of the median nerve in line with published recommendations ^[@ref-38]^. This can also be used to model ion channel function. We will explore the relationship of these measures to the risk of developing neuropathic pain and the relationship to pain intensity. Training will be provided to clinicians performing threshold tracking measurements to ensure the reliability of the data and harmonisation of nerve excitability protocols in all centres.

***Skin biopsy for intra-epidermal nerve fibre assessment***

Intra-epidermal nerve fibre density (IENFD) is a validated tool for the assessment of small fibre pathology ^[@ref-39]^. In DOLORisk IENFD is determined from skin biopsy samples taken in accordance with published guidelines provided by the European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the utilisation of skin biopsy samples in the diagnosis of peripheral neuropathies (see supplementary file: Skin biopsy for intraepidermal nerve fibre assessment) ^[@ref-39]^. The skin biopsies are taken at the end of the clinical assessment once all relevant investigations are completed. Participants do not under undergo a skin biopsy if they are on warfarin or found to have other contraindications.

***Quantitative sensory testing***

*Static tests*

Quantitative sensory testing (QST) is a measure of sensory perception in response to a defined sensory stimulus. This test can show abnormalities in sensory function and be used to generate a sensory profile in respect to different sensory modalities assessing both gain and loss of function. For bilateral neuropathic pain disorders such as peripheral neuropathy QST is performed unilaterally on the dorsum of the most affected foot. For unilateral neuropathic pain disorders QST is performed bilaterally in the affected area and the contralateral equivalent body region (which acts as a helpful comparator). QST is performed according to a modification of the previously published protocol of the German Research Network on Neuropathic Pain (DFNS) ^[@ref-40]^. These modifications were made in order to improve efficiency when performed in a restricted timescale. The wind up ratio (WUR) is not performed unless the patient is having conditioned pain modulation (CPM) tests in which case it will be helpful to have a measure of central sensitisation. WUR is performed on the forearm instead of the dorsum of the hand in order to minimise the influence of peripheral sensory loss on detection of central processes. Thermal sensory limen is performed in those patients with peripheral neuropathy but not in peripheral nerve injury (a situation where it is less informative). The assessment of mechanical pain sensitivity is shortened and two rounds of tests are performed instead of the five rounds included in the full DFNS protocol. All other tests are identical to the DFNS protocol and all study sites will be trained and certificated in the DFNS protocol to promote standardisation. QST data is entered into the data analysis system, [Equista](http://www.neuro.med.tu-muenchen.de/dfns/arzt/qstform.html) (version 1.2.2., CASQUAR GmbH), which was developed by the DFNS. Equista transforms the raw QST data into z-scores thus normalising for age, gender, and the body location of testing ^[@ref-41],\ [@ref-42]^. A z-score of zero is equal to the mean of the population. A score of greater or less than two standard deviations from the mean indicates gain of function or loss of function, respectively.

*Dynamic tests*

Conditioned pain modulation (CPM) provides insight into an individual's endogenous analgesic mechanisms ^[@ref-43],\ [@ref-44]^. It can be assessed in a non-invasive manner and may be a key vulnerability factor for chronic pain and has also been shown to be predictive of treatment response. The protocol for CPM testing is in keeping with published recommendations (see supplementary file: Protocol for conditioned pain modulation) ^[@ref-45],\ [@ref-46]^.

***Genetics***

DNA is extracted from a whole blood sample collected at recruitment. The analysis will follow three complementary approaches: genome-wide association studies (GWAS); whole exome sequencing to identify rare, high-impact coding variants; and targeted sequencing of selected candidate genes.

Definition of neuropathy
------------------------

The participants who undergo the extended protocol are assessed for neuropathy (when this is considered a relevant possibility by the investigator e.g. a patient with diabetes) and in all cases are also graded for neuropathic pain. To diagnose peripheral neuropathy, we use the criteria outlined by Tesfaye, *et al.* ^[@ref-47]^ that classify neuropathy as possible, probable or confirmed:

Possible peripheral neuropathy is defined as the presence either of sensory symptoms, i.e. decreased sensation (e.g. "asleep, numbness"), positive neuropathic sensory symptoms (e.g. prickling or stabbing, burning or aching pain) predominantly in the toes, feet, or legs; or of sensory signs, i.e. symmetric decrease of distal sensation or unequivocally decreased or absent ankle reflexes.

Probable peripheral neuropathy corresponds to any two or more of the following: sensory symptoms (as above), decreased distal sensation, or unequivocally decreased or absent ankle reflexes.

Confirmed peripheral neuropathy is defined as the presence of an abnormality of nerve conduction studies and a sensory symptoms OR signs of neuropathy. If nerve conduction studies are normal, a validated measure of small fibre neuropathy (abnormal thermal thresholds on QST or reduced intra-epidermal nerve fibre density) may be used ^[@ref-47]^.

Definition of neuropathic pain
------------------------------

The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP)'s grading for neuropathic pain ^[@ref-48]^ is used to grade neuropathic pain for all study participants recruited. Each study participant's pain is assessed using these published criteria as below. Possible neuropathic pain must fulfil criteria 1 and 2. Probable neuropathic pain must fulfil criteria 1, 2 and 3. Definite neuropathic pain must fulfil all 4 criteria.

1.  Pain with a distinct neuroanatomically plausible distribution, e.g. pain symmetrically distributed in the extremities -- completion of body map and clinical history.

2.  A history suggestive of a relevant lesion or disease affecting the peripheral or central somatosensory system -- e.g. diagnosis of diabetes mellitus and a history of neuropathy symptoms including decreased sensation, positive sensory symptoms, e.g. burning, aching pain mainly in the toes, feet or legs.

3.  Demonstration of distinct neuroanatomically plausible distribution of neuropathic pain -- e.g. presence of clinical signs of peripheral neuropathy, i.e. decreased distal sensation or decreased/absent ankle reflexes.

4.  Demonstration of the relevant lesion or disease by at least one confirmatory test -- e.g. abnormality on either the nerve conduction tests or IENFD.

In the large, population-based cohorts, the core protocol permits the 'entry level' approximation to a classification of "possible neuropathic pain", based on the NeuroPPIC phenotyping consensus ^[@ref-14]^. This includes positive responses to the DN4 screening questionnaire, and relevant site and severity of pain as outlined above. Additional information on diagnosis of any pain conditions will be available.

Cohorts
=======

DOLORisk is a multi-centre cross-sectional and longitudinal observational study. Multiple cohorts with neuropathic pain from different causes will be included. Each cohort has its own specific inclusion and exclusion criteria, and follows a specific recruitment flow ( [Figure 1](#f1){ref-type="fig"}; [Table 3](#T3){ref-type="table"}-- [Table 5](#T5){ref-type="table"}).

![DOLORisk Recruitment flow.\
DK = Denmark, FR = France.](wellcomeopenres-3-16455-g0000){#f1}

###### Inclusion and exclusion criteria for invitation to the population cohort for the DOLORisk protocol.

  --------------------------------------------------------------------------------------------------------------------------
                          Inclusion criteria                                     Exclusion criteria
  ----------------------- ------------------------------------------------------ -------------------------------------------
  **Population cohort**   •   Previous participation with GoDARTS or GS:SFHS.\   •   Unable to give consent.\
                          •   Existing consent to be re-contacted.\              •   No current postal address available.\
                          •   Identified as being currently alive.\              •   Identified as having died.
                          •   Currently has a postal address on file.\           
                          •   ≥ 18 years.                                        

  --------------------------------------------------------------------------------------------------------------------------

###### Inclusion and exclusion criteria for the cross-sectional cohorts for the DOLORisk protocol.

  ------------------------------------------------------------------------------------------------------------------------------------------------
                         Inclusion criteria                                                 Exclusion criteria
  ---------------------- ------------------------------------------------------------------ ------------------------------------------------------
  **Peripheral**\        •   ≥18 years with a diagnosis of peripheral neuropathy\           •   Pregnant.\
  **neuropathic pain**        based on a prior clinical assessment combined with\           •   Incapacity to give consent or to complete\
                              supportive clinical investigations such as abnormal nerve\         the study questionnaires due to insufficient\
                              conduction studies, reduced intraepidermal nerve or\               language command or mental deficiencies.\
                              abnormal findings on quantitative sensory testing.\           •   Concurrent severe psychological or\
                         •   Symptoms highly suggestive of neuropathy that in the\               psychiatric disorders.\
                              judgement of the clinical researcher are suitable for the\    •   Moderate to severe pain from other\
                              study even if they do not fulfil other inclusion criteria.\        causes that may confound assessment\
                         •   Patients who do not fulfil any of the exclusion criteria.\          or reporting of pain (e.g. spinal canal\
                         •   Diabetes cohorts: Type 1 or Type 2 diabetes                         stenosis).\
                                                                                            •   Central nervous lesions, which may\
                                                                                                 complicate somatosensory testing.\
                                                                                            •   Patients who are in the opinion of the\
                                                                                                 investigator unsuitable for participation in\
                                                                                                 the study.

  **Extreme**\           •   ≥16 years with a set of symptoms that resemble those\          •   Pregnant.\
  **phenotypes**              seen on Paroxysmal Extreme Pain Disorder, Familial\           •   Incapacity to give consent or to complete\
                              Episodic Pain Syndrome or Erythromelalgia.\                        the study questionnaires due to insufficient\
                         •   Existing diagnosis of Paroxysmal Extreme Pain Disorder or\          language command or mental deficiencies.\
                              Familial Episodic Pain Syndrome or Erythromelalgia.\          •   Concurrent severe psychological or\
                         •   Reduced pain sensibility.\                                          psychiatric disorders, especially severe\
                         •   First degree relatives of patients who meet diagnostic\             claustrophobia.\
                              criteria for Paroxysmal Extreme Pain Disorder, Familial\      •   Moderate to severe pain arising as a\
                              Episodic Pain Syndrome, Erythromelalgia or inability to\           consequence of other disorders causing\
                              experience pain.\                                                  pain but that are not associated with those\
                         •   Patients who do not fulfil any of the exclusion criteria.           mentioned before as channelopathies.\
                                                                                            •   Central nervous system diseased that may\
                                                                                                 complicate the somatosensory testing.\
                                                                                            •   Patients who are in the opinion of the\
                                                                                                 investigator unsuitable for participation in\
                                                                                                 the study.\
                                                                                            •   Treatment or topical capsaicin cream/\
                                                                                                 ointment or Lidocaine patch within 30 days\
                                                                                                 prior to Day 1 on the skin area that will be\
                                                                                                 tested.\
                                                                                            •   Presence of oedema or any skin condition\
                                                                                                 at the ankle level that may interfere with the\
                                                                                                 microneurography procedure.
  ------------------------------------------------------------------------------------------------------------------------------------------------

###### Inclusion and exclusion criteria for the longitudinal cohorts *for the DOLORisk protocol*.

  ----------------------------------------------------------------------------------------------------------------------------------------------
                     Inclusion criteria                                        Exclusion criteria
  ------------------ --------------------------------------------------------- -----------------------------------------------------------------
  **Chemotherapy**   •   ≥18 years.\                                           •   Known metastatic cancer.\
                     •   Diagnosed with high-risk colorectal cancer.\          •   Previous treatment with chemotherapy.\
                     •   Planned adjuvant treatment with oxaliplatin and\      •   Significant mental illness.\
                         flourouracil (5-FU) or capecitabine (Pro 5-FU).       •   Alcohol abuse.\
                                                                               •   Known diabetes.\
                                                                               •   Significant neuropathic diseases.\
                                                                               •   Spinal cord stenosis.\
                                                                               •   Peripheral vascular diseases (Fontaine \>2).\
                                                                               •   Chronic pain with a pain intensity on a 0-10 numeric\
                                                                                   rating scale \>5.\
                                                                               •   Patients who do not speak, read or understand Danish.

  **Thoracotomy**    •   ≥ 18 years.\                                          •   Mental incapacity or language barriers precluding\
                     •   Scheduled for lung cancer resection performed\            adequate understanding of study procedures.\
                         via thoracoscopy and/or thoracotomy, including\       •   Current alcohol or substance abuse according to the\
                         lobectomy, bilobectomy, pneumonectomy,\                   site investigator's medical judgement.\
                         resection of the tracheobronchial bifurcation,\       •   Unsuitability for participation in the study for any other\
                         wedge resection, sleeve resection and\                    reason, e.g. due to a significant serious underlying\
                         combinations hereof.\                                     condition (e.g. other cancer or AIDS), as determined by\
                     •   Willingness and ability to comply with study\             the site investigator/manager.\
                         procedures as judged by the site investigator/\           ADDITIONALLY in FR:\
                         manager.\                                             •   Previous surgery on the same area.\
                     •   Expected availability for follow-up throughout the\   •   Surgery targeting only the pleura or mediastinum.\
                         study.                                                •   Peripheral neurological pathology or central (brain\
                                                                                   damage, multiple sclerosis) susceptible to interfere with\
                                                                                   the evaluation of the post-operative pain.\
                                                                               •   History of significant mental illness: psychosis, severe\
                                                                                   depression having motivated a hospitalisation, suicide\
                                                                                   attempt.\
                                                                               •   Current major depressive episode at the time of the\
                                                                                   evaluation.\
                                                                               •   Abuse of drug or psychoactive substance during the last\
                                                                                   six months.\
                                                                               •   Patients participating in another protocol of biomedical\
                                                                                   research.

  **Mastectomy**     •   Women ≥ 18 years.\                                    •   Cognitive or psychological disorders incompatible with\
                     •   Scheduled for breast cancer resection performed\          the respect and/or the understanding of the protocol.\
                         via lumpectomy (partial or segmental mastectomy)\     •   Current alcohol or substance abuse according to the site\
                         or mastectomy with or without sentinel lymph node\        investigator\'s medical judgement.\
                         biopsy and axillary lymph node dissection, and\       •   Unsuitability for participation in the study for any other\
                         any combinations hereof.\                                 reason, e.g. due to a significant serious underlying\
                     •   Affiliated to a social security scheme.\                  condition (e.g. other cancer or AIDS), as determined by\
                     •   Danish/French language (read, written and\                the site investigator.\
                         spoken).\                                             •   Previous surgery on the same area.\
                     •   Willingness and ability to comply with study\         •   Peripheral neurological pathology or central (brain\
                         procedures as judged by the site investigator.\           damage, multiple sclerosis) susceptible to interfere with\
                     •   Expected availability for follow-up throughout the\       the evaluation of the post-operative pain.\
                         study.                                                •   History of significant mental illness: psychosis, severe\
                                                                                   depression having motivated a hospitalisation, suicide\
                                                                                   attempt.\
                                                                               •   Current major depressive episode at the time of\
                                                                                   assessment.\
                                                                               •   Abuse of drug or psychoactive substance during the last\
                                                                                   six months\
                                                                               •   Participating in another protocol of biomedical research.\
                                                                               •   Other cancer or AIDS.\
                                                                               •   Scheduled for bilateral mastectomy.\
                                                                               •   Presence of chronic pain before the breast cancer\
                                                                                   surgery.\
                                                                               •   Workplace accident, litigation or search for\
                                                                                   compensation.
  ----------------------------------------------------------------------------------------------------------------------------------------------

Population cohort
-----------------

Generation Scotland: the Scottish Family Health Study (GS:SFHS) ^[@ref-49]^ and Genetics of Diabetes Audit and Research Tayside (GoDARTS) ^[@ref-50]^ are population-based genetic epidemiology studies. DNA, socio-demographic and clinical data are available for 24,000 GS:SFHS participants and 20,000 (9,000 with diabetes) GoDARTS participants across Scotland. Participants will be contacted by post and invited to complete the DOLORisk core protocol. After 18 months, enrolled participants will be invited to complete the same questionnaire to assess development, progression or remission of any pain. For the population cohorts it is estimated that between 7% (GS:SFHS) and 25% (GoDARTS) of those with chronic pain will have neuropathic pain ^[@ref-51]^. Therefore, 1,500 participants with neuropathic pain and 3,000 controls are anticipated from GS:SFHS and 2,000 participants with neuropathic pain and 4,000 controls are anticipated from GoDARTS.

Cross-sectional cohorts assessed with the extended protocol
-----------------------------------------------------------

Patients with peripheral neuropathic pain, e.g. diabetic neuropathy, chemotherapy-induced neuropathy, and traumatic nerve injury will be recruited by the University of Oxford, Imperial College London, Kiel University, Technion -- Israel Institute of Technology, Neuroscience Technologies, and Aarhus University, from both primary and secondary care. Patients with extreme pain phenotypes, such as insensitivity to pain, will also be recruited. The study participants will be assessed as per the DOLORisk extended protocol.

Longitudinal cohorts assessed with the extended protocol
--------------------------------------------------------

Patients undergoing mastectomy, thoracotomy or receiving chemotherapy will be recruited by INSERM (French National Institute for Health and Medical Research) and Aarhus University. The surgical cohort of study participants will be recruited among patients scheduled for lung surgery or breast cancer surgery. The study participants receiving chemotherapy will be recruited from patients diagnosed with colorectal cancer. All study participants in this cohort will undergo the extended protocol before surgery or receiving chemotherapy. Thereafter, at different times ranging from 4 to 12 months participants will be re-assessed, using the extended protocol, to determine the development of neuropathic pain ( [Figure 1](#f1){ref-type="fig"}). We expect to include 50 patients scheduled to undergo chemotherapy and 590 patients scheduled for lung or breast surgery.

Data analysis
=============

Sample size calculation
-----------------------

The sample size for the protocol is largely based on the primary outcome, which is the number of participants to explore the genetic risk factors of neuropathic pain. The main comparison will be between those study participants diagnosed with neuropathic pain and those are diagnosed with no pain or pain of non-neuropathic nature. We will also be exploring physiological and psychosocial risk factors and these outcomes will require smaller sample sizes.

For example, based on the CaTS power calculator ^[@ref-52]^, we will have 80% power in an additive model with p=10 ^-8^, prevalence of neuropathic pain in the general population of 8%, with a disease allele frequency of 0.30 (GS:SFHS) or 0.38 (GoDARTS), and therefore a genotype relative risk of 1.34. Based on the CaTS GWAS power calculator ^[@ref-52]^, with 1,500 cases and 3,000 controls (as in the GS:SFHS cohort), we will have 82.7% power to identify SNP associations with a significance level of 5×10 ^−8^, assuming an additive model, a minor disease allele frequency of 0.3, a genotypic relative risk of 1.35, and a prevalence of the diabetic neuropathic pain in the general population of 10% ^[@ref-1]^.

For the extended phenotyping of painful versus painless diabetic neuropathy (estimating 1000 subjects in each group) we will have 80% power to detect an allelic odds ratio of 1.7 at genome wide significance level (p\<5×10 ^-8^). We will also be able to cross-validate between these cohorts. We have identified a further cohort of diabetic neuropathy individuals in Sweden who will be available for replication genotyping. In collaboration with the [SUMMIT consortium](http://www.imi-summit.eu/), we would also like to combine data across diverse diabetic complications in order to enhance the power to detect genetic determinants of the microvascular complications of diabetes.

Further sample size calculations have been performed depending on the individual outcome measures being measured.

***QST***

Sample size was determined according to the warm detection threshold data for patients with diabetes ^[@ref-5]^. This calculation revealed a minimum sample size of 34 was required per group for a power of \>0.8 (difference in means 2.0; standard deviation 4.3; a = 0.05).

***CPM***

A cohort of 53 subjects gives an 80% power in between group differences of \>0.25 standard deviations equivalent to 1.0 to 1.6 range on the 0-10 pain numerical rating scale using a typical QST parameter such as conditional pain modulation.

Data management
===============

The [University of Dundee's Health Informatics Centre (HIC) Services](https://www.dundee.ac.uk/hic) acts as a hub for data management. HIC Services develops bespoke software to support secure data collection, provides recruitment support for clinical studies and manages a data entry service. All services provided by HIC are delivered within a secure Safe Haven environment to ensure data are managed safely and in compliance with Data Protection legislation. All HIC processes are governed by approved Standard Operating Procedures. The questionnaire data is collected during the visit either on a paper clinical report form, or on a digital one, depending on the centres. The data is then entered by the investigator in the DOLORisk database through a bespoke interface. In order to limit input errors, the interface includes data checks and acceptable ranges, for instance for age, height and weight. Oxford have access to the whole dataset and perform checks on the quality and completeness of the entered data. Issues such as missing data are fed back to the respective centres so that they can be addressed.

GoDARTS and GS:SFHS datasets are already hosted on secure HIC servers. Participants' identities will be shielded at all times from the research team, according to the secure SOPs.

External datasets generated by DOLORisk will be sent to HIC in anonymised format. When ready, these updated datasets will be transferred to the analytics platform held on a separate server and network from the HIC data management function within a remote-access Safe Haven for research projects. It has full analytical functionality including software (e.g. R and SAS) and is supported by powerful processing. Remote access to the Safe Haven analytics platform is available to approved project researchers, after they have signed appropriate agreements. No individual-level data can be removed from the Safe Haven, but summary outputs of analysis are released, after prompt screening by HIC to ensure that no potentially identifiable information is included to reduce the risk of accidental disclosure. Clinical phenotype data will be linked in anonymised format to genomic outputs.

Ethics and dissemination
========================

Ethic approvals were obtained at the national level. Details can be found in [Table 6](#T6){ref-type="table"}. Participants are included in the protocol only after having given their written informed consent. Their decision whether to take part, or withdrawal during the course of the study, in no way alters their normal medical care. The signed informed consent is obtained by the clinician in charge of the patient or the healthy volunteer.

###### DOLORisk cohorts approvals.

NT: Neuroscience Technologies. INSERM : Institut National de la Santé Et de la Recherche Médicale. CS: cross-sectional. Pro: prospective. REC: Research Ethics Committee. ANSM: Agence nationale de sécurité du médicament et des produits de santé (national agency for medicines and health products safety). CPP : Comité de protection des personnes (ethical research committee). CCTIRS: Comité consultatif sur le traitement de l\'information en matière de recherche dans le domaine de la santé (advisory committee on data processing in health research). CNIL: Commission nationale de l'informatique et des libertés (data protection authority).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Centre             CS or\            Aetiology       Anticipated\       Ethics\               Ethics\                                                                                    Registration link                                                                                                                                       Reference                      End date
                     Pro                               sample size        committee             reference                                                                                                                                                                                                                                                                         
  ------------------ ----------------- --------------- ------------------ --------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ------------
  Dundee             Pro               Mixed           5500               Tayside\              05/S1401/89                                                                                [https://www.hra.nhs.uk/planning-](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/dolorisk-dundee/)\   Smith, *et al*. ^[@ref-49]^    April 2018
                                                                          Committee\                                                                                                       [and-improving-research/](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/dolorisk-dundee/)\                                           
                                                                          on Medical\                                                                                                      [application-summaries/research-](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/dolorisk-dundee/)\                                   
                                                                          Research Ethics                                                                                                  [summaries/dolorisk-dundee/](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/dolorisk-dundee/)                                         

  Yorkshire & The\   15/YH/0285                                                                                                                                                                                                                                                                                                                                                   
  Humber - South\                                                                                                                                                                                                                                                                                                                                                                 
  Yorkshire REC                                                                                                                                                                                                                                                                                                                                                                   

  Dundee             Pro               Diabetes        3000               Tayside\              053/04                                                                                     [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02783469)\                                                                Hebert, *et al*. ^[@ref-50]^   
                                                                          Committee\                                                                                                       [NCT02783469](https://clinicaltrials.gov/ct2/show/NCT02783469)                                                                                                                         
                                                                          on Medical\                                                                                                                                                                                                                                                                                             
                                                                          Research Ethics                                                                                                                                                                                                                                                                                         

  Yorkshire & The\   15/YH/0285                                                                                                                                                                                                                                                                                                                                                   
  Humber - South\                                                                                                                                                                                                                                                                                                                                                                 
  Yorkshire REC                                                                                                                                                                                                                                                                                                                                                                   

  Oxford             CS                Extreme\        100                NRES\                 12/LO/0017                                                                                 [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02696746)\                                                                                               January\
                                       phenotypes                         Committee\                                                                                                       [NCT02696746](https://clinicaltrials.gov/ct2/show/NCT02696746)                                                                                                                         2019
                                                                          London -\                                                                                                                                                                                                                                                                                               
                                                                          Riverside                                                                                                                                                                                                                                                                                               

  CS                 Diabetes          300             West London\       10/H0707/35           [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02672059)\   Themistocleous,\                                                                                                                                        June 2019                      
                                                       REC 3                                    [NCT02672059](https://clinicaltrials.gov/ct2/show/NCT02672059)                             *et al*. ^[@ref-5]^                                                                                                                                                                    

  Imperial           CS                Diabetes        200                London -\             16/LO/1470                                                                                                                                                                                                                                                                        
                                                                          Bromley REC                                                                                                                                                                                                                                                                                             

  Kiel               CS                Mixed           200                Ethics\               D454/16                                                                                    [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02666456)\                                                                                               March\
                                                                          Committee of\                                                                                                    [NCT02666456](https://clinicaltrials.gov/ct2/show/NCT02666456)                                                                                                                         2019
                                                                          the Faculty of\                                                                                                                                                                                                                                                                                         
                                                                          Medicine of Kiel\                                                                                                                                                                                                                                                                                       
                                                                          University                                                                                                                                                                                                                                                                                              

  Technion           CS                Diabetes        200                Helsinki\             0052-15-RNB                                                                                [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02402361)\                                                                                               July 2018
                                                                          Committee of\                                                                                                    [NCT02402361](https://clinicaltrials.gov/ct2/show/NCT02402361)                                                                                                                         
                                                                          Rambam Health\                                                                                                                                                                                                                                                                                          
                                                                          Care Campus                                                                                                                                                                                                                                                                                             

  NT                 CS                Diabetes        100                Clinical\             2016/43-NEU-\                                                                              [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02985294)\                                                                                               March\
                                                                          Research Ethics\      MC Mutual                                                                                  [NCT02985294](https://clinicaltrials.gov/ct2/show/NCT02985294)                                                                                                                         2019
                                                                          Committee\                                                                                                                                                                                                                                                                                              
                                                                          (CREC) of\                                                                                                                                                                                                                                                                                              
                                                                          idcsalud\                                                                                                                                                                                                                                                                                               
                                                                          in Catalonia                                                                                                                                                                                                                                                                                            

  CS                 Traumatic         100                                                                                                                                                                                                                                                                                                                                        

  Aarhus             CS                Diabetes        350                Central\              Diabetic\                                                                                  [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02947828)\                                                                                               May 2018
                                                                          Denmark Region\       neuropathy, 1-\                                                                            [NCT02947828](https://clinicaltrials.gov/ct2/show/NCT02947828)                                                                                                                         
                                                                          Committees on\        10-72-130-16                                                                                                                                                                                                                                                                      
                                                                          Health Research\                                                                                                                                                                                                                                                                                        
                                                                          Ethics                                                                                                                                                                                                                                                                                                  

  CS                 Chemotherapy      70              Central\           Chronic\              [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02654691)\                                                                                                                                                           April 2017                     
                                                       Denmark Region\    neuropathy\           [NCT02654691](https://clinicaltrials.gov/ct2/show/NCT02654691)                                                                                                                                                                                                                    
                                                       Committees on\     following\                                                                                                                                                                                                                                                                                              
                                                       Health Research\   chemotherapy,\                                                                                                                                                                                                                                                                                          
                                                       Ethics             20110158                                                                                                                                                                                                                                                                                                

  Pro                Chemotherapy      50              Central\           Acute and\                                                                                                                                                                                                                                                                                              
                                                       Denmark Region\    chronic\                                                                                                                                                                                                                                                                                                
                                                       Committees on\     neuropathy after\                                                                                                                                                                                                                                                                                       
                                                       Health Research\   oxaliplatin, 1-10-\                                                                                                                                                                                                                                                                                     
                                                       Ethics             72-154-16                                                                                                                                                                                                                                                                                               

  Aarhus             Pro               Post-surgical   250                Central\              Understanding\                                                                             [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT03124511)\                                                                                               November\
                                                                          Denmark Region\       risk factors and\                                                                          [NCT03124511](https://clinicaltrials.gov/ct2/show/NCT03124511)\                                                                                                                        2019
                                                                          Committees on\        determinants for\                                                                          [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02960971)\                                                                                               
                                                                          Health Research\      neuropathic pain\                                                                          [NCT02960971](https://clinicaltrials.gov/ct2/show/NCT03124511)                                                                                                                         
                                                                          Ethics                after lung or\                                                                                                                                                                                                                                                                    
                                                                                                breast surgery,\                                                                                                                                                                                                                                                                  
                                                                                                1-10-72-254-16\                                                                                                                                                                                                                                                                   
                                                                                                and 1-10-72-\                                                                                                                                                                                                                                                                     
                                                                                                23-17                                                                                                                                                                                                                                                                             

  INSERM             Pro               Post-surgical   340                ANSM                  160106B-32,\                                                                               [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT02944721)\                                                                                               November\
                                                                                                160287B-32                                                                                 [NCT02944721](https://clinicaltrials.gov/ct2/show/NCT02944721)                                                                                                                         2020

  CPP                CPP/2-16, 16\                                                                                                                                                                                                                                                                                                                                                
                     03 18                                                                                                                                                                                                                                                                                                                                                        

  CCTIRS             16-331bis, 16-\                                                                                                                                                                                                                                                                                                                                              
                     330bis                                                                                                                                                                                                                                                                                                                                                       

  CNIL               2007306 v 0,\                                                                                                                                                                                                                                                                                                                                                
                     1251929 v 0                                                                                                                                                                                                                                                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Where possible, datasets will be made publicly available once the study is completed. Gene variants associated with neuropathic pain risk will be entered into the existing PainNetworks database ^[@ref-53]^ that undergoes longstanding curation by the London Pain Consortium. Transcriptional profiling data will be entered into [painnetworks.org](http://painnetworks.org/) and [ArrayExpress](https://www.ebi.ac.uk/arrayexpress/). We will enrich this with anonymised normative data on sensory profiling and physiological variables. It will be possible to download clinical screening tools from the [DOLORisk website](http://dolorisk.eu/).

Findings will be communicated to the scientific community via peer-reviewed publications (open access), and presentations at conferences. DOLORisk has partnered with patient organisations supporting people with pain and neuropathy-related disorders such as Pain Association Scotland, the InDependent Diabetes Trust, and Fibromyalgia Action UK. The results of the study will be sent to the organisations periodically.

Current study status
====================

Recruitment started in 2016 and is ongoing in all centres. As of December 2017, 1,915 participants in GoDARTS and 7,240 participants in Generation Scotland have returned the questionnaires of the core protocol. 1,062 participants have been recruited throughout the rest of the centres according to the extended protocol. All recruitment and follow-up activities are expected to be completed by mid-2019.

Data availability
=================

No data are associated with this article.

Supplementary material {#SM1}
======================

**Protocol for conditioned pain modulation**

Click here for additional data file.

**Skin biopsy for intraepidermal nerve fibre assessment**

Click here for additional data file.

10.21956/wellcomeopenres.16455.r34754

Referee response for version 2

Haroutounian

Simon

1

Referee

Department of Anesthesiology and Washington University Pain Center, Washington University School of Medicine, St. Louis, MO, USA

**Competing interests:**No competing interests were disclosed.

4

2

2019

Version 2

The authors have addressed all my previous comments.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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Version 1

This is a multicentre, international, prospective observational study with the goal to investigate in a systematic manner neuropathic pain due to multiple aetiologies targeting to enrol large number of patients, especially those with diabetic neuropathy.  Authors state that the primary objective is to identify a number of factors that would influence and lead to development of neuropathic pain and the association of genetic factors with risk of developing and maintaining neuropathic pain.

This is a very ambitious and large undertaking, likely to generate a large amount of information and hopefully be a great source of publications.

A lot of thought and work has been put into this project and a few things would be worth attending to in attempt to make it more productive. These would be comments in addition to those expressed by Dr. Haroutounian with which I agree.

Statement of objectives is very general and imprecise, such as inclusion of environmental factors and none is ever addressed in the grant. It is not clear if this is matter of language used or lack of focus but for the reader of this project more precise definition of Objectives would be more meaningful.

Regarding the location of pain, the current description is detailed but probably not meaningfully useful and it is unlikely to lead to interpretable results. Yes, it will be possible to check of boxes as to location of pain but the current schemata will not provide any useful information. 

Foundation for conducting studies with EEG and threshold tracking is lacking and though rationale is presented it is scientifically insufficient at best and very weak.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Pascal

Mathilde

Nuffield Department of Clinical Neurosciences, University of Oxford, UK

**Competing interests:**No competing interests were disclosed.
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Thank you for your feedback. We have amended the article based on Dr Haroutounian's comments, which you said you agreed with -- please see our response to him in addition to our reply to you below.

*1. Statement of objectives is very general and imprecise, such as inclusion of environmental factors and none is ever addressed in the grant. It is not clear if this is matter of language used or lack of focus but for the reader of this project more precise definition of Objectives would be more meaningful.*

Thank you for this point. We intended "environmental" to mean "non-genetic".  We agree that in this sense, it is indeed not used correctly when used for the first time in the description of the objectives. We believe the other uses are appropriate. We apologise for the confusion of the first use of the word, which we have now deleted.

*2. Regarding the location of pain, the current description is detailed but probably not meaningfully useful and it is unlikely to lead to interpretable results. Yes, it will be possible to check of boxes as to location of pain but the current schemata will not provide any useful information.*

The core protocol has a list of locations but the extended protocol uses this list and additionally a body map for the patient to complete, which will provide detailed information. The list of locations is a pragmatic approach in large questionnaire based surveys and was used to allow harmonisation with Generation Scotland and other ongoing epidemiological studies. This approach is consistent with the recommendations of the Neuropathic pain phenotyping by consensus recommendations of NeuPSIG  (van Hecke et al, 2015). As part of our analysis, we are testing this approach to phenotype neuropathic pain, and intend to publish an analysis of the validity and feasibility of the approach. We have the advantage that in the extended cohort we can directly assess the outcome of using a list of locations versus the use of a body map. We will revise any future phenotyping efforts accordingly.

*3. Foundation for conducting studies with EEG and threshold tracking is lacking and though rationale is presented it is scientifically insufficient at best and very weak.*

We have now expanded on both these points in the protocol in order to provide a clearer rationale for these investigations
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Version 1

Pascal and colleagues present a protocol for a multicenter observational study (DOLORisk) for understanding risk factors and determinants of neuropathic pain of various etiologies. The authors should be congratulated for this massive and ambitious undertaking - the study is likely to provide enormous insight into risk factors associated with the development of neuropathic pain.

Below are several comments authors may want to consider:

The first point is related to my response related to \"partial\" presentation of sufficinet details of methods in order to be replicated.

Some of the multiple assessment in the protocol, even when following guidelines, can have certain methodological variability.

Procedures such as CPM and skin biopsy refer to general guidelines,  and may be challenging to reproduce without more detailed instructions. It would be advisable if the authors added an appendix with a summary of the specific CPM protocol, and skin biopsy protocol.

[Additional comments:]{.ul}

\"Characterization of pain\" section: It is unclear whether the medications will be recorded as individual drugs, as therapeutic groups vs pharmacological classes, and whether doses/duration will be recorded. It would be useful if the researchers provide the details in the protocol, and to describe how they intend to present these data.

In \"nerve conduction studies\" section the last sentence notes that if prior nerve conduction tests are available, repeat tests will not be performed. Do authors intend to assign an acceptable window to the timeline? i.e. - if a patient has had DPN for 10 years, and has NCV results from 8 years ago, would those considered valid for the study purposes?

Data management: it is not clear if there is a computer-based data collection system with direct data entry from each site, which then undergoes QC, or whether the data are collected on paper-pencil CRFs, then entered to a some electronic format (e.g. spreadsheets) and transmitted (via email?) to the University of Dundee HIC Services. This is important for controlling the steps where potential errors can occur, and it would be useful to provide more specific steps of data collection, entry and central storage.

Table 5: the exclusion criteria for thoracotomy and mastectomy cohorts are quite different in terms of components not related directly to the surgery (e.g. cognitive disorders, substance use). Is there a rationale for these differences?

Table 5: the sentence \"Receiving another treatment than oxaliplatin and flourouracil (5-FU) or capecitabine (Pro 5-FU).\" might be better worded as \"receiving treatment other than oxaliplatin\...\". In addition, the adjuvant FOLFOX regimen often includes Leucovorin. For such \"hard\" criteria of excluding anything besides 5-FU/Capecitabline and oxaliplatin, the investigators may want to add leucovorin. Also - some centers add bevacizumab to adjuvant FOLFOX regimens - consider either allowing or explicitly excluding these patients.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Pascal

Mathilde

Nuffield Department of Clinical Neurosciences, University of Oxford, UK

**Competing interests:**No competing interests were disclosed.
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Thank you for taking the time to read our study protocol and for your constructive feedback. We have addressed your comments below.

*1. The first point is related to my response related to \"partial\" presentation of sufficinet details of methods in order to be replicated. Some of the multiple assessment in the protocol, even when following guidelines, can have certain methodological variability. Procedures such as CPM and skin biopsy refer to general guidelines,  and may be challenging to reproduce without more detailed instructions. It would be advisable if the authors added an appendix with a summary of the specific CPM protocol, and skin biopsy protocol.*

The harmonisation of the protocols across our centres is absolutely essential in DOLORisk and we appreciate your feedback to make this protocol more useful and reproducible to other people. We have added the CPM protocol and the skin biopsy protocol in the appendices of the article. The CPM protocol also exists in video format: <https://www.youtube.com/watch?v=jL9GgdsyHtA>.

*2. \"Characterization of pain\" section: It is unclear whether the medications will be recorded as individual drugs, as therapeutic groups vs pharmacological classes, and whether doses/duration will be recorded. It would be useful if the researchers provide the details in the protocol, and to describe how they intend to present these data.*

Yes we are recording individual drugs. Wherever possible the dosage is also indicated. This section has been amended to further clarify this point.

*3. In \"nerve conduction studies\" section the last sentence notes that if prior nerve conduction tests are available, repeat tests will not be performed. Do authors intend to assign an acceptable window to the timeline? i.e. - if a patient has had DPN for 10 years, and has NCV results from 8 years ago, would those considered valid for the study purposes?*

Indeed, we take into account the results of previous nerve conduction studies if they are less than two years old, regardless of how long a participant has had DPN for. We have now added this clarification to the article.

*4. Data management: it is not clear if there is a computer-based data collection system with direct data entry from each site, which then undergoes QC, or whether the data are collected on paper-pencil CRFs, then entered to a some electronic format (e.g. spreadsheets) and transmitted (via email?) to the University of Dundee HIC Services. This is important for controlling the steps where potential errors can occur, and it would be useful to provide more specific steps of data collection, entry and central storage.*

The questionnaire data are collected during the visit either on a paper clinical report form, or on a digital one, depending on the participating centre. The data are then entered manually by the investigator in the DOLORisk database through a bespoke interface. In order to limit input errors, the interface includes data checks and acceptable ranges, for instance for age, height and weight. Oxford have access to the whole dataset and perform checks on the quality and completeness of the entered data. Issues such as missing data are sent back to the respective centres so that they can be addressed. The section on data management has been amended to include this information.

*5. Table 5: the exclusion criteria for thoracotomy and mastectomy cohorts are quite different in terms of components not related directly to the surgery (e.g. cognitive disorders, substance use). Is there a rationale for these differences?*

Most criteria are common between the mastectomy cohort and the thoracotomy cohort. Only point 4 (history of significant mental illness) might make a real difference between the French and the Danish cohort (some criteria are specific to procedure such as surgery targeting the pleura in thoracotomy). The reason for adding the exclusion criteria of significant mental illness is that our French centre wanted to avoid having problematic patients in terms of psychiatric morbidities. However the Danish centre is recording co-morbidities and we can exclude these cases at the analysis stage to match the French cohort if we feel that this is required for alignment.

The exclusion criterion of "cognitive or psychological disorders incompatible with the respect and/or the understanding of the protocol" in the mastectomy cohort is mirrored in the thoracotomy cohort by "mental incapacity or language barriers precluding adequate understanding of study procedures." To clarify how the criteria match between the two cohorts, we have re-arranged the order of the exclusion criteria in the mastectomy cohort.

*6. Table 5: the sentence \"Receiving another treatment than oxaliplatin and flourouracil (5-FU) or capecitabine (Pro 5-FU).\" might be better worded as \"receiving treatment other than oxaliplatin\...\". In addition, the adjuvant FOLFOX regimen often includes Leucovorin. For such \"hard\" criteria of excluding anything besides 5-FU/Capecitabline and oxaliplatin, the investigators may want to add leucovorin. Also - some centers add bevacizumab to adjuvant FOLFOX regimens - consider either allowing or explicitly excluding these patients.*

We do allow leucovorin (although rare at the centre where the standard is oxaliplatin iv and capecitabine as tablet (XELOX)) while bevacizumab is not used as adjuvant therapy in Denmark, which is the centre recruiting the chemotherapy cohort. However, what we actually meant with the criteria was in fact "Not receiving oxaliplatin and flourouracil (5-FU) or capecitabine (Pro 5-FU)", but as this is already an inclusion criteria, we have now deleted this sentence.
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